Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer

Phase 2

Completed

Conditions: Gastric Cancer
Adenocarcinoma of the Esophagogastric Junction

Interventions: Drug: Docetaxel
Drug: 5-Fluorouracil
Drug: Oxaliplatin
Drug: folinic acid

First Posted Date: 2008-08-19

Last Posted Date: 2012-09-19

Lead Sponsor: Krankenhaus Nordwest

Target Recruit Count: 143

Registration Number: NCT00737373

Locations: 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany

Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer

Phase 2

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Abraxane
Drug: Cetuximab
Drug: Cisplatin
Drug: 5-FU
Radiation: Radiation (Post induction)

First Posted Date: 2008-08-18

Last Posted Date: 2020-09-09

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 30

Registration Number: NCT00736944

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma

Phase 2

Terminated

Conditions: Esophageal Cancer

Interventions: Drug: 5-FU
Drug: Cisplatin
Drug: Taxotere
Biological: Cetuximab
Radiation: Radiation during chemoradio-immunotherapy

First Posted Date: 2008-08-14

Last Posted Date: 2015-03-09

Lead Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie

Target Recruit Count: 50

Registration Number: NCT00735345

Locations: 🇦🇹
Universitätsklinik Innsbruck, Innsbruck, Austria
🇦🇹
Universitätsklinikum Graz, Graz, Austria
🇦🇹
A.ö. Landeskrankenhaus Leoben, Leoben, Austria

and more 4 locations

Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Biological: cetuximab
Drug: cisplatin
Drug: docetaxel
Drug: fluorouracil
Procedure: computed tomography
Procedure: positron emission tomography
Procedure: quality-of-life assessment
Radiation: 3-dimensional conformal radiation therapy
Radiation: intensity-modulated radiation therapy

First Posted Date: 2008-07-24

Last Posted Date: 2020-04-07

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 20

Registration Number: NCT00721513

Locations: 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab

Phase 3

Terminated

Conditions: Colorectal Cancer

Interventions: Biological: bevacizumab
Drug: fluorouracil
Drug: irinotecan hydrochloride
Drug: leucovorin calcium
Drug: oxaliplatin

First Posted Date: 2008-07-22

Last Posted Date: 2015-03-11

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 184

Registration Number: NCT00720512

Locations: 🇮🇹
Ospedale Santa Croce, Cuneo, Italy
🇮🇹
Ospedale degli Infermi - ASL 12, Biella, Italy
🇮🇹
Azienda Usl 8 Arezzo, Arezzo, Italy

and more 18 locations

Combination Chemotherapy and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Biological: bevacizumab
Drug: fluorouracil
Drug: irinotecan hydrochloride
Drug: leucovorin calcium
Drug: oxaliplatin

First Posted Date: 2008-07-22

Last Posted Date: 2015-03-11

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 509

Registration Number: NCT00719797

Locations: 🇮🇹
A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona - Ancona (An) Oncologia Medica, Ancona, Italy
🇮🇹
P.O. Zona Aretina - Ospedale S. Donato Di Arezzo - Arezzo (Ar) Oncologia Medica, Arezzo, Italy
🇮🇹
Ospedale Della Valdinievole - Pescia (Pt) Oncologia Medica, Pescia, Italy

and more 41 locations

Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor

Phase 1

Completed

Conditions: Gastric Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: docetaxel
Drug: fluorouracil
Drug: oxaliplatin

First Posted Date: 2008-07-08

Last Posted Date: 2019-02-26

Lead Sponsor: Northwestern University

Target Recruit Count: 59

Registration Number: NCT00711243

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States

Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer

Phase 2

Completed

Conditions: Advanced Colorectal Cancer
Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum

Interventions: Drug: bevacizumab
Drug: ABT-869
Drug: oxaliplatin
Drug: folinic acid
Drug: fluorouracil

First Posted Date: 2008-07-01

Last Posted Date: 2013-05-15

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 159

Registration Number: NCT00707889

Locations: 🇺🇸
Site Reference ID/Investigator# 11341, Chapel Hill, North Carolina, United States
🇺🇸
Site Reference ID/Investigator# 20801, Philadelphia, Pennsylvania, United States
🇦🇺
Site Reference ID/Investigator# 18581, Bedford Park, Australia

and more 43 locations

Docetaxel, Cisplatin and Fluorouracil in Treating Patients with Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

Phase 2

Active, not recruiting

Conditions: Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma
Sinonasal Undifferentiated Carcinoma
Stage II Nasal Cavity and Paranasal Sinus Cancer AJCC V8
Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC V8
Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC V8
Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC V8

Interventions: Drug: Carboplatin
Other: Chemoradiotherapy
Drug: Cisplatin
Procedure: Definitive Surgical Resection
Drug: Docetaxel
Drug: Fluorouracil
Procedure: Quality-of-Life Assessment
Radiation: Radiation Therapy

First Posted Date: 2008-06-30

Last Posted Date: 2024-12-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00707473

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Docetaxel in Node Positive Adjuvant Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: 5-fluorouracil
Drug: Docetaxel
Drug: Doxorubicin
Drug: Cyclophosphamide

First Posted Date: 2008-06-03

Last Posted Date: 2011-02-16

Lead Sponsor: Sanofi

Target Recruit Count: 1491

Registration Number: NCT00688740

Locations: 🇮🇱
sanofi-aventis Administrative office, Natanya, Israel
🇬🇧
Sanofi-aventis adminsitrative office, Guildford Surrey, United Kingdom
🇸🇪
Sanofi-Aventis Administrative Office, Bromma, Sweden

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy